Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 13-23

  Lai, Jie ^a,b   Lu, Yi ^a   Yin, Zongning ^b   Hu, Fuqiang ^c   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Beagle dogs; Bioavailability; Cubosomes; Cyclosporine A; Glyceryl monooleate; Nanoparticles; Oral drug delivery

Indexed keywords

CYCLOSPORIN A; GLYCEROL OLEATE; NANOPARTICLE; POLOXAMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; DOGS; DRUG COMPOUNDING; MALE; METABOLIC CLEARANCE RATE; MOUTH; NANOCAPSULES; OLEIC ACID; PARTICLE SIZE; POLOXAMER;

CANIS FAMILIARIS;

EID: 77951189574     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ®) in organ transplantation. Drugs. 2001;61:1957-2016.
2. Hebert MF. Contributions of hepatic and intestinal matabolism and Pglycoprotein to cyclosporin ans tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27:201-214.
3. Tjai JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa. Br J Clin Pharmacol. 1991;31:344-346
4. ®). Drugs. 1995;50:924-941.
5. Vonderscher J, Meinzer A. Rationale for the development of Sandimmun Neoral. Transplant Proc. 1994;26:2925-2927.
6. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994;11:301-304.
7. Dai J, Nagai T, Wang X, et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280: 229-240.
8. Wang XQ, Dai JD, Chen Z, et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release. 2004;97:421-429.
9. Wang XQ, Huang J, Dai JD, et al. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid. Int J Pharm. 2006;322:146-153.
10. Italia JL, Bhatt DK, Bhardwaj V, et al. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmun Neoral. J Control Release. 2007;119: 197-206.
11. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249:101-108.
12. Müller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317:82-89.
13. Aliabadi HM, Brocks DR, Lavasanifar A. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials. 2005;26:7251-7259.
14. Guo J, Wu T, Ping Q, et al. Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv. 2005;12:35-39.
15. Lee EJ, Lee SW, Choi HG, et al. Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int J Pharm. 2001;218:125-131.
16. Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. Int J Pharm. 2001;216:17-21.
17. Shah NM, Parikh J, Namdeo A, et al. Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. J Nanosci Nanotechnol. 2006;6:2967-2973.
18. Liu C, Wu J, Shi B, et al. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm. 2006;32:115-123.
19. Chen MC, Wang JL, Tzen JT. Elevating bioavailability of cyclosporine a via encapsulation in artificial oil bodies stabilized by caleosin. Biotechnol Prog. 2005;21:1297-1301.
20. Kim SJ, Choi HK, Lee YB. Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats. Int J Pharm. 2002;249:149-156.
21. Thomson AB, Schoeller C, Keelan M, et al. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol. 1993;71:531-555.
22. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-248.
23. Barauskas J, Johnsson M, Tiberg F. Self-aseembled lipid supersture beyond vesicles and liposomes. Nano Lett. 2005;5:1615-1619.
24. Yang D, Armitage B, Marder SR. Cubic liquid-crystalline nanoparticles. Angew Chem Int Ed. 2004;43:4402-4409.
25. Esposito E, Cortesi R, Drechsler M, et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22:2163-2173.
26. Garg G, Saraf S, Saraf S. Cubosomes: an overview. Biol Pharm Bull. 2007;30:350-353.
27. Chung H, Kim J, Um JY, et al. Self-asembled "nanocubicle" as a carrier for peroral insulin delivery. Diabetologia. 2002;45:448-451.
28. Um JY, Chung H, Kim KS, et al. In vitro cellular interaction and absorption of dispersed cubic particles. Int J Pharm. 2003;253: 71-80.
29. Lai J, Chen J, Lu Y, et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS Pharm Sci Tech. 2009;10:960-966.
30. Gustafsson J, Ljusberg-Wahren H, Almgren M. Cubic lipid-water phase dispersed into submicron particles. Langmuir. 1996;12:4611-4613.
31. Jin Y, Ai P, Xin R, et al. Morphological transformation of self-assembled nanostructures prepared from cholesteryl acyldidanosine and the optimal formulation of nanoparticulate system: Effect of solvents, acyl chain length and poloxamer 188. J Colloid Interf Sci. 2008;326:275-282.
32. Missirlis D, Kawamura R, Tirelli N, et al. Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci. 2006;29:120-129.
33. Chimalakonda AP, Shah RB, Mehvar R. High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard. J Chromatogr B. 2002;772:107-114.
34. Katneni K, Charman SA, Porter CJ. An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. J Pharm Pharmacol. 2008;60:1311-1319.
35. Korjamo T, Heikkinen AT, Mönkkönen J. Analysis of unstirred water layer in in vitro permeability experiments. J Pharm Sci. 2009;98: 4469-4479.
36. Boyd BJ, Whittaker DV, Khoo SM, et al. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm. 2006;309:218-226.
37. Boyd BJ, Khoo SM, Whittaker DV, et al. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavail-ability for a model poorly water soluble drug in rats. Int J Pharm. 2007;340:52-60.
38. Lee KW, Nguyen TH, Hanley T, et al. Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs. Int J Pharm. 2009;365: 190-199.